Sensitizing Tumor Cells to Immune-Mediated Cytotoxicity
The molecular basis underlying tumor destruction in vivo by specific antitumor CD8+T cells remains unclear. We propose that the local production of certain tumor necrosis factor (TNF)-family members (death ligands) may be more important for tumor destruction in vivo than previously thought. Also, the apoptotic response of some tumor cells to the TNF-family member TRAIL can be augmented by the proteasome inhibitor bortezomib (Velcade). Thus, bortezomib may sensitize tumor cells to T cell-mediated cytotoxicity and could potentially improve the beneficial effects of immunotherapy.
KeywordsNatural Killer Cell Tumor Antigen Adoptive Transfer Tumor Rejection Death Ligand
Unable to display preview. Download preview PDF.
- Gattinoni, L., Powell, D.J., Rosenberg, S.A. and Restifo, N.P. (2006) Adoptove immuno-therapy for cancer: building on success. Nature 6, 383–393.Google Scholar
- Gillmore, R., Xue, S-A., Holler, A., Kaeda, J., Hadjiminas, D., Healy, V., Dina, R., Parry, S.C., Bellantuono, I., Ghani, Y., Coombes, R.C., Waxman, J. and Strauss, H.J. (2006) Detection of Wilms’ tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Human Cancer Biol. 12, 34–42.Google Scholar
- Seki, N., Brooks, A.D., Carter, C.R.D., Back, T.C., Parsoneault, E.M., Smyth, M.J., Wiltrout, R.H. and Sayers, T.J. (2002) Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168, 3484–3492.PubMedGoogle Scholar
- Sun, K., Welniak, L., Panoskaltsis-Mortari, A., O’Shaughnessy, M.J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J.S., Blazar, B.R., Sayers, T.J. and Murphy, W.J. (2004) Inhibition of acute graft-versus-host disease with retention of graft -versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl. Acad. Sci. U.S.A. 101, 8120–8125.CrossRefPubMedGoogle Scholar